155 related articles for article (PubMed ID: 8131699)
1. Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac.
Melarange R; Gentry C; Durie M; O'Connell C; Blower PR
Dig Dis Sci; 1994 Mar; 39(3):601-8. PubMed ID: 8131699
[TBL] [Abstract][Full Text] [Related]
2. Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.
Melarange R; Gentry C; Blower PR; Toseland CD; Spangler R
Eur J Rheumatol Inflamm; 1994; 14(2):15-22. PubMed ID: 7744129
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies.
Spangler RS
Am J Med; 1993 Aug; 95(2A):35S-39S. PubMed ID: 8357001
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration.
Melarange R; Blower P; Spangler R
Eur J Rheumatol Inflamm; 1994; 14(2):23-7. PubMed ID: 7744130
[TBL] [Abstract][Full Text] [Related]
5. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative studies with indomethacin.
Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
Dig Dis Sci; 1992 Dec; 37(12):1847-52. PubMed ID: 1473433
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): comparison with indomethacin.
Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
Agents Actions; 1992; Spec No():C82-3. PubMed ID: 1442340
[TBL] [Abstract][Full Text] [Related]
7. The in vitro effects of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone, on rat gastric mucosal eicosanoid synthesis and metabolism.
Melarange R; Spangler R; Hoult JR
Prostaglandins Leukot Essent Fatty Acids; 1996 Sep; 55(3):195-200. PubMed ID: 8931119
[TBL] [Abstract][Full Text] [Related]
8. The unique pharmacologic profile of nabumetone.
Blower PR
J Rheumatol Suppl; 1992 Nov; 36():13-9. PubMed ID: 1474529
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1 alpha production and on bile salt-induced changes in gastric mucosal function.
Melarange R; Rashbrook LC
J Pharm Pharmacol; 1987 Sep; 39(9):717-20. PubMed ID: 2445949
[TBL] [Abstract][Full Text] [Related]
10. Neutropenia does not prevent etodolac- or indomethacin-induced gastrointestinal damage in the rat.
Melarange R; Gentry C; Toseland CD; Smith PH; Fuller J
Dig Dis Sci; 1995 Dec; 40(12):2694-703. PubMed ID: 8536533
[TBL] [Abstract][Full Text] [Related]
11. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function.
Jeremy JY; Mikhailidis DP; Barradas MA; Kirk RM; Dandona P
Br J Rheumatol; 1990 Apr; 29(2):116-9. PubMed ID: 2108782
[TBL] [Abstract][Full Text] [Related]
12. Effect of the antiinflammatory prodrug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo.
Jeremy JY; Thompson CS; Mikhailidis DP; Dandona P
Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):195-9. PubMed ID: 2281122
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory efficacy and gastrointestinal irritancy: comparative 1 month repeat oral dose studies in the rat with nabumetone, ibuprofen and diclofenac.
Melarange R; Gentry C; O'Connell C; Blower PR
Agents Actions Suppl; 1991; 32():33-7. PubMed ID: 2069095
[TBL] [Abstract][Full Text] [Related]
14. Theoretical mechanism for the gastrointestinal safety of etodolac: selective sparing of cytoprotective prostaglandins.
Dvornik D; Lee DK
Clin Rheumatol; 1989 Mar; 8 Suppl 1():16-24. PubMed ID: 2525980
[TBL] [Abstract][Full Text] [Related]
15. Etodolac: effect on prostaglandin concentrations in gastric mucosa of rats.
Lee D; Dvornik D
Life Sci; 1985 Mar; 36(12):1157-62. PubMed ID: 3157036
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution?
Dandona P; Jeremy JY
Drugs; 1990; 40 Suppl 5():16-24. PubMed ID: 2081487
[TBL] [Abstract][Full Text] [Related]
17. Comparative gastrointestinal blood loss associated with placebo, aspirin, and nabumetone as assessed by radiochromium (51Cr).
Lussier A; Davis A; Lussier Y; Lebel E
J Clin Pharmacol; 1989 Mar; 29(3):225-9. PubMed ID: 2786009
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation.
Giuliano F; Ferraz JG; Pereira R; de Nucci G; Warner TD
Eur J Pharmacol; 2001 Aug; 426(1-2):95-103. PubMed ID: 11525777
[TBL] [Abstract][Full Text] [Related]
19. Effect of nabumetone and aspirin on colonic mucosal bleeding time.
Basson MD; Panzini L; Palmer RH
Aliment Pharmacol Ther; 2001 Apr; 15(4):539-42. PubMed ID: 11284783
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of nabumetone, naproxen, piroxicam, and diclofenac on rat gastric irritancy following acute exposure to OTC non-steroidal anti-inflammatory agents and other gastric irritants.
Carryl OR; Spangler RS
Scand J Rheumatol; 1995; 24(6):336-41. PubMed ID: 8610216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
